Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.

NCT00359164 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Macular Degeneration

Interventions

DRUG: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
DRUG: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
DRUG: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab

Sponsor

University of British Columbia